Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation
Top Cited Papers
Open Access
- 22 June 2020
- Vol. 70 (3), 628-629
- https://doi.org/10.1136/gutjnl-2020-321913
Abstract
No abstract availableKeywords
Funding Information
- Chongqing Special Research Project for Prevention and Control of COVID-19 (cstc2020jscx－fyzx0103F)
This publication has 11 references indexed in Scilit:
- Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort studyGut, 2021
- Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in ChinaJournal of Hepatology, 2020
- COVID-19: Unanswered questions on immune response and pathogenesisJournal of Allergy and Clinical Immunology, 2020
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialThe Lancet, 2020
- A Dynamic Immune Response Shapes COVID-19 ProgressionCell Host & Microbe, 2020
- Severe liver failure during SARS-CoV-2 infectionGut, 2020
- Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injuryJournal of Hepatology, 2020
- COVID-19: Abnormal liver function testsJournal of Hepatology, 2020
- Clinical Features of COVID-19-Related Liver Functional AbnormalityClinical Gastroenterology and Hepatology, 2020
- COVID-19 and the liver: little cause for concernThe Lancet Gastroenterology & Hepatology, 2020